Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory DLBCL
NCT07197307Phase 2Recruiting
- Sponsor
- Universität Münster
- Start
- Oct 2025
- Primary completion
- Apr 2030
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of loncastuximab tesirine, epcoritamab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), follicular lymphoma (FL), sponsored by Universität Münster. Started Oct 2025; status: recruiting.
02
Drugs
loncastuximab tesirineepcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07197307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197307.